Hosted on MSN4h
Samsung Bioepis launches autoimmune disease treatment in U.S.
Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, said Tuesday it has launched its biosimilar product ...
Pharmabiz22m
Biocon Biologics launches Yesintek biosimilar to Stelara in US
Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...
Biocon share price up 2% as arm launches Yesintek in US; check details here
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...
ENDPOINTS NEWS3d
Te­va launch­es Ste­lara biosim­i­lar at 85% dis­count as wider field emerges
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...
Managed Healthcare Executive3d
Second Biosimilar of Stelara Launches
Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
Daily3h
Biocon Biologics unveils Yesintek biosimilar to Stelara in US
YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Biocon Biologics launches biosimilar alternative to Stelara in the US
YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...
India Infoline6h
Biocon Biologics introduces stelara biosimilar YESINTEK in US
Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...